Sign in
Not yet taking people in FrancePhase 2

Imaging diseased hand joints in finger osteoarthritis and rheumatoid arthritis with 99mTc-NTP15-5

Tests 99mTc-NTP15-5 imaging to find diseased hand joints in adults with arthritis.

Key facts

Who runs it
Centre Jean Perrin
Where
Clermont-Ferrand, FranceSee the 2 sites
Registry title
functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study
Status
Not yet recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
1 May 2026
Expected to end
1 Jun 2028
Type of study
Interventional
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with hand osteoarthritis of the fingers or with rheumatoid arthritis, diagnosed less than 5 years ago, who have finger pain and no anti-inflammatory pills (NSAIDs) in use.

Age
18 years or older
Sex
All sexes
Disease stage
Finger osteoarthritis (DOA) with symptoms, diagnosed less than 5 years ago, finger pain above 4 out of 10. Or rheumatoid arthritis diagnosed less than 5 years ago, with finger pain above 4 out of 10 and active joint inflammation (synovitis) seen clinically and on ultrasound.
Earlier treatment
People with osteoarthritis must stop NSAIDs for at least 8 days. People with rheumatoid arthritis cannot be on biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6, anti-JAK). No corticosteroid injection into a hand joint in the month before the 99mTc-NTP 15-5 injection.
Biomarker or test result
Rheumatoid arthritis must be certain by the ACR/EULAR criteria. Karnofsky Index above 70%. Women who can have children need a negative pregnancy blood test within 7 days before the injection.

Main reasons for not taking part

  • Ongoing use of NSAIDs
  • Pregnant or breastfeeding
  • BMI above 30
  • Past surgery on the hand bones or joints, or soft tissue surgery on the hands in the last 6 months
  • Known allergy to an ingredient of the 99mTc-NTP 15-5 solution

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Both Groups : Karnofsky Index > 70%
  • DOA Group : stopping NSAIDs for at least 8 days
  • Both groups: Obtaining written, signed and dated informed consent
  • Both groups: Affiliation to a health insurance plan
  • Both groups : For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on a GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days prior to injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months without any other cause and FSH and oestradiol levels consistent with those of the post-menopausal period
  • Both groups : Ability and willingness to comply with clinic visits, tests, and the protocol
  • RA Group : certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria
  • RA Group : symptomatic (finger pain > 4 /10 on a numerical scale)
  • RA Group :active synovitis (clinical and ultrasound)
  • DOA Group : certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale)

Who cannot take part

  • Both groups : Inability to undergo the trial’s medical follow-up due to geographical, family, social, or psychological reasons. These conditions must be discussed with the patient prior to enrollment in the study
  • Both groups : Treatment by local joint corticosteroid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5
  • RA Group : Patients with a history of hand AD
  • Both groups : History of osteoarticular surgery on the hands
  • Both groups : History of soft tissue surgery on the hands within the past 6 months
  • Both groups : History of known allergy to the excipients contained in the 99mTc-NTP 15-5 solution
  • Both groups : Patients under the age of 18 years old
  • Both Groups : Ongoing NSAID usage
  • RA Group : Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment
  • Both groups : Pregnant or breastfeeding patients
  • Both groups : BMI > 30
  • Both groups : Individuals deprived of their liberty, under guardianship/curatorship, or subject to judicial protection

Where in France

  • Centre Jean PerrinClermont-Ferrand, FranceNot yet recruiting
  • University Hospital Of Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting

About the trial

What the trial wants to find out

to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group: digital osteoarthritis (DOA) and rheumatoid arthritis (RA)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study
Plain-language title
Imaging diseased hand joints in finger osteoarthritis and rheumatoid arthritis with 99mTc-NTP15-5Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
24 July 2026